Current Report Filing (8-k)
03 3월 2023 - 8:06PM
Edgar (US Regulatory)
0001410098
false
0001410098
2023-03-02
2023-03-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 2, 2023
CORMEDIX INC.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-34673 |
|
20-5894890 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
300 Connell Drive, Suite 4200
Berkeley Heights, NJ |
|
07922 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (908) 517-9500
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2, below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common stock, $0.001 par value |
|
CRMD |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On March 2, 2023, CorMedix Inc. (the “Company”)
issued a press release announcing regulatory and manufacturing updates related to U.S. Food and Drug Administration compliance and remediation
activities at the Company’s contract manufacturing organization and heparin active pharmaceutical ingredient supplier. The Company
further outlined manufacturing pathways for resubmission of its New Drug Application, and their respective timelines.
A copy of the press release is filed as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CORMEDIX INC. |
|
|
|
Date: March 3, 2023 |
By: |
/s/ Joseph Todisco |
|
Name: |
Joseph Todisco |
|
Title: |
Chief Executive Officer |
CorMedix (AMEX:CRMD)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
CorMedix (AMEX:CRMD)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024
CorMedix Inc (아메리카 증권거래소)의 실시간 뉴스: 최근 기사 0
More Cormedix Inc. News Articles